Project Grant R43CA285033
Award Date
9/3/24
Completion Date
8/31/25
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $400,000 Project Grant to O2M Technologies LLC to improve the image acquisition speed of their Single Point Imaging (SPI) oxygen mapping technology. SPI is a subset of the company's Pulse Electron Paramagnetic Resonance Imaging (PEPRI) method, which can generate high-resolution 3D partial oxygen pressure (pO2) maps in live tissues and tumors. The goal of this project is to...
This $407,113 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will fund research by Trustees of Boston University to develop a new bio-orthogonal mid-infrared photothermal (MIP) imaging technology to study cancer metabolism. The key products and services to be delivered include: Building a library of nitrile-based probes to sense important molecular events and nutrient metabolism in cancer cells using the MIP imaging approach. Developing a...
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a for-profit limited liability company based in Baltimore, Maryland. The grant, awarded from February 1, 2025 to January 31, 2027, aims to develop a prototype web/cloud-based quantitative SPECT reconstruction software system for clinical trials and dosimetry of emerging radiopharmaceutical cancer therapies,...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of a novel nanopore-based sequencing technology capable of accurately characterizing repetitive DNA sequences, which are known to play a significant role in cancer progression but have been challenging to analyze using current...
The National Cancer Institute (NCI) awarded a $549,536 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Trustees of Dartmouth College to develop a comprehensive 3D wearable near-infrared (NIR) spectral tomography system for early prediction of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy. The project aims to integrate flexible circuit strips into a sleek, 64-channel wearable breast interface and apply 3D image reconstruction...
This $419,133 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of the "AsciTesPredictTM" platform - a novel "ex vivo tumor biosensor" technology using single-cell analysis to evaluate cancer cell identities and therapeutic sensitivities. The key product under this 3-year award is to harden the AsciTesPredictTM technology for wider deployment in research settings to...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an x-ray dual-energy cone-beam microCT (DECB microCT) system for intraoperative imaging of lumpectomy specimens during breast-conserving surgery (BCS). The $2,020,098 award to the University of Chicago will support the following key objectives over the 5-year project period: Develop the DECB microCT technology to provide enhanced...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $658,336 to Rarecyte, Inc. to develop the ORION2 instrument, a novel system for highly multiplexed spatial profiling of tumor and tissue samples. The ORION2 will combine advanced methods for quantifying 10-60 protein markers in tissue sections at subcellular resolution with machine learning algorithms to prioritize and acquire optimized high-resolution images. This...
This $593,383 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop an AI-augmented, multimodal, label-free nonlinear optical microscopy system for rapid and precise diagnosis of thyroid cancer and lymph node metastasis. The award supports the creation of a compact, portable, AI-integrated label-free microendoscope designed to fit within a core biopsy needle. This device is intended to enable...
This $427,095 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of a novel microfluidic droplet-based platform (MDP) technology at Northeastern University. The objective is to generate and analyze a 3D biomimetic multicellular immunogenic tumor model that can establish multiple levels of hypoxia, investigate spatiotemporal interactions between the tumor microenvironment and...